Coenzym Q10 til behandling af senfølger efter COVID-19 (QVID studiet)

Phase 1

• Conditions: ong Term COVID-19 illness; MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestations; Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]

• Registration Number: EUCTR2020-005961-16-DK
• Lead Sponsor: ars Jørgen Østergaard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-15
• Last Update Posted: 9 May 2022

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1.Age above 18 years.
2.Able to give informed consent.
3.History of documented SARS-CoV-2 infection either by RT-PCR or antibody test.
4.Symptoms related to LTC, defined as being investigated, diagnosed and followed by specialized infectious diseases physicians in the Long Term COVID-19 Outpatient Clinic, Central Region of Denmark, Aarhus University Hospital. This clinic covers all LTC patients referred from general practitioners and regional hospitals in Region Midtjylland.
5. Symptoms not attributable to other co-morbidity/condition.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 110
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

1.Symptoms of acute COVID-19, as defined by The Danish Health Authorities/Sundhedsstyrelsen.
2.Pregnant or breast-feeding women.
3.Known allergy to soy or peanuts.
4.Individuals with reduced kidney or liver-function.
5.Patients in anticoagulant therapy with warfarin or similar vitamin K antagonists.
6.Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified